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MONOTHERAPY OF ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL
PROSTATECTOMY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER: A
COMPARATIVE EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS
Liu J, Shi L, Sartor O
Tulane University, New Orleans, LA, USA
OBJECTIVES: There is no consensus regarding the optimal treatment for localized
prostate cancer. This study aimed to examine the comparative effectiveness of
monotherapy of either primary androgen deprivation therapy (PADT) or radical
prostatectomy (RP) in terms of overall survival rate.METHODS:Male patients with
localized prostate cancer were identified in the Veterans Affairs Veterans Inte-
grated Service Network 16 data warehouse (January, 2003-June, 2006), with one
year baseline and at least 3-year follow-up (till 06/2009). Eligible patients (18-75
years old) had no other cancer history and used PADT ormonotherapy of RPwithin
6 months after the first diagnosis of prostate cancer. The overall survival from
initiation of index treatment was analyzed using Kaplan-Meier method and Cox
proportional hazard regression, adjusted for age, race, marital status, insurance
type, cancer stage, Charlson comorbidity index, alcohol and tobacco use. RESULTS:
The age was 66.2(6.07) [Mean(SD)] years in 211 PADT patients, 59.9(6.15) in 215 RP
patients. During the follow-up of 4.2(0.95) years, the cumulative incidence of death
was 29 (13.74%) among PADT patients and 6 (2.79%) among RP patients (p0.001).
The overall 3-year survival rate was 89.57% in PADT and 98.60% in RP (p0.001).
Patients who received PADT had almost 4 times as high mortality risk as those
using RP (HR 3.820, 95% CI1.483 to 9.845, p0.006). CONCLUSIONS: Overall sur-
vival rate following RP among localized prostate cancer patients was significantly
higher than that after PADT, controlling for other covariates. More research among
a larger population with longer follow-up are warranted to confirm this finding.
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ESTIMATED EFFECTS OF THE NATIONAL BREAST AND CERVICAL CANCER
EARLY DETECTION PROGRAM ON CERVICAL CANCER MORTALITY
Ekwueme DU1, Uzunangelov V2, Hoerger T2, Saraiya M1, Miller J1, Hall I1, Benard V1,
Royalty J1, Li C1
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OBJECTIVES: The National Breast and Cervical Cancer Early Detection Program (NB-
CCEDP) is the largest organized cancer screening program for low-income, un-insured
and under-insured women in the United States. The program’s effectiveness in in-
creasing the life expectancy of participating women has never been measured. We
estimated the benefits of NBCCEDP-funded cervical cancer screening (Program) in
terms of life-years (LYs) saved compared to No Program and No Screening scenarios.
METHODS: Based on an existing model developed by Myers et al., we constructed a
cervical cancer simulationmodel bymodifying the age and screening schedule of the
cohort to reflect screening frequency for NBCCEDP participants from 1991-2007. We
estimated screening habits in the absence of the program based on data from the
1990-2005 National Health Interview Survey. We performed Markov cohort analysis
for each age in the 18-64 range and calculated an overall weighted average using the
age distribution at first NBCCEDP Pap test for screening.Weighted averages were pro-
duced for three scenarios –women receiving testing from theNBCCEDP (the Program),
women receiving testing from alternative sources in the absence of the program (No
Program), and women receiving no testing at all (No Screening). We compared LY
estimates for 69,100womendetectedwith humanpapillomavirus infection, low-and-
high-grade squamous intraepithelial lesions or cervical cancer under the program to
the counterfactual of having their disease undetected under No Program and No
Screening scenarios. RESULTS: From 1991-2007, we estimate that the Program added
10,369 LYs to the total lifespan of tested women when compared to No Program, and
101,509 LYswhen compared toNoScreening. Furthermore, the Programprevented an
estimated 325 cervical cancer deaths relative to No Program, and 3,825 relative to No
Screening. CONCLUSIONS: These estimates suggest that NBCCEDP cervical cancer
screening may have reduced mortality among medically underserved women in
the United States.
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Roth J1, Carlson JJ2, Steuten L3, Veenstra D1
1University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA,
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OBJECTIVES: To assess the value of additional research for ERCC1 expression test-
ing to guide adjuvant chemotherapy decisions in fully resected Stage I non-small
cell lung cancer (NSCLC).METHODS:We refined a previously-developed decision-
analytic model to estimate the expected value of perfect information (EVPI) and
expected value of sample information (EVSI) for two treatment strategies: 1) ERCC1
testing to inform adjuvant chemotherapy decisions, with ERCC1 patients receiv-
ing no chemotherapy and ERCC1- patients receiving chemotherapy; 2) standard
care, with all patients receiving no chemotherapy. Model parameters and uncer-
tainty ranges were derived from a retrospective analysis of the International Ad-
juvant Lung Cancer Trial, published literature, and government sources. The af-
fected population was derived from SEER incidence estimates, and examined over
a discounted 10-year time horizon. RESULTS: At a willingness-to-pay of $150,000
per quality-adjusted life year, ERCC1 and standard care strategies resulted in av-
erage net-benefits of $630,500 and $625,200, respectively. The ERCC1 and standard
care strategies produced greater net-benefit in 64% and 36% of 10,000 simulations,
respectively. The average net-benefit difference was $14,000 in simulations where
the standard care strategy was optimal. With an affected population of 233,825;
EVPI was $1.2 billion. Preliminary estimates suggest an EVSI of approximately $20
million at plausible sample sizes. CONCLUSIONS: Considerable value could be
realized through additional research to reduce uncertainty about the comparative
health outcomes of ERCC1 and standard care strategies. The EVPI of $1.2 billionwas
driven by the large 10-year affected population, probability that ERCC1 testing is
not the optimal strategy, and consequences of selecting the non-optimal strategy.
Forthcoming results will enable estimation of the expected net-benefit of sam-
pling, which compares the EVSI of various study designs and sample sizes to the
cost of conducting such studies. These findings can assist stakeholders in priori-
tizing funding for ERCC1 research relative to alternative research investments.
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PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR
ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND
VOMITING AMONG MEDICARE PATIENTS WITH CANCER
Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc., Charlotte, NC, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: To assess the rate of uncontrolled chemotherapy induced nausea and
vomiting (CINV) associated with palonosetron initiation versus other 5-hydroxy
tryptamine3-receptor antagonists (5-HT3-RAs) among Medicare patients with cancer
on chemotherapy (CT) treatment in a hospital outpatient setting. METHODS: Medi-
care patients with a cancer diagnosis initiating CT and anti-emetic prophylaxis with
palonosetron (Group 1) and other 5-HT3-RAs (Group 2) for the first time (index date)
between April 1, 2007 – March 31, 2009 were identified from the Premier Perspective
database. Inclusion criteria were no evidence of nausea and vomiting, CT, and anti-
emetic medication in the 6-month pre-index date period and 36-consecutivemonths
of data submission. A negative binomial distribution generalized linear multivariate
regression model estimating the rate of CINV events on CT emetogenicity and cycle
matched groups in the follow-up period (first of eight CT cycles or six months post-
index date) was developed after adjusting for several demographic and clinical
variables. RESULTS: Of 4799 identified patients, 962 initiated palonosetron (Group 1;
20.1%). Group 1 patients were significantly younger [70.4 (SD: 9.3) versus 71.6 (9.0)
years; p0.0001], comprisedmore females [52.9%versus 48.6%; p0.0001], lessAfrican
Americans [8.7% vs. 11.3%] and more Hispanic patients [6.3% versus 2.5%]; all
p0.0001,more highly andmoderately emetogenic CT [33.6% versus 20.7% and; 47.3%
versus 40.3%, respectively; p0.0001], and more lung and breast [30.9% vs. 24.9% and
12.3% vs. 9.6%, respectively; p0.0001]. In the follow-up period, the regression model
predicted a 11.8%decrease in theCINVevents per CT cycle for Group 1 patients versus
Group 2 patients; p0.05. CONCLUSIONS: In this retrospective hospital outpatient
study, aftermatching for CT emetogenicity and cycle and adjusting for other potential
confounders, Medicare patients with cancer initiated on palonosetron were more
likely to experience a significantly lower rate of CINV events per CT cycle versus those
initiating other 5-HT3-RAs.
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